IDEAS home Printed from https://ideas.repec.org/a/inm/orinte/v37y2007i5p472-487.html
   My bibliography  Save this article

Research and Development Project Valuation and Licensing Negotiations at Phytopharm plc

Author

Listed:
  • Pascale Crama

    (Department of Management Science and Operations, London Business School, Regent's Park, London NW1 4SA, United Kingdom)

  • Bert De Reyck

    (Department of Management Science and Innovation, University College London, London WC1E 6BT, United Kingdom, and Department of Management Science and Operations, London Business School, Regent's Park, London NW1 4SA, United Kingdom)

  • Zeger Degraeve

    (Department of Management Science and Operations, London Business School, Regent's Park, London NW1 4SA, United Kingdom)

  • Wang Chong

    (Phytopharm plc, Corpus Christi House, Godmanchester, Cambridgeshire PE29 2HY, United Kingdom)

Abstract

We describe a research and development project-valuation model developed for Phytopharm plc, a pharmaceutical development and functional food company based in Cambridgeshire, United Kingdom. Phytopharm uses the model to value the projects in its research and development portfolio, and in licensing negotiations with potential product development and marketing partners. We include different valuation methods, including net present value, decision analysis, and Monte Carlo simulation. We also consider the technological risks of product development, as well as the uncertainty of commercial success. In addition to determining a value for a product in development, the model proposes appropriate licensing contract structures. A typical licensing contract specifies milestone payments and royalties to be paid by the licensee to the licensor. The contract structures adhere to an agreed-upon equitable split of the project value between the two parties. The model also generates critical information during the negotiation meetings, including break-even analyses, trade-offs, and bargaining zones. Phytopharm is currently deploying the model for use with its entire project portfolio.

Suggested Citation

  • Pascale Crama & Bert De Reyck & Zeger Degraeve & Wang Chong, 2007. "Research and Development Project Valuation and Licensing Negotiations at Phytopharm plc," Interfaces, INFORMS, vol. 37(5), pages 472-487, October.
    • Handle: RePEc:inm:orinte:v:37:y:2007:i:5:p:472-487
    DOI: 10.1287/inte.1060.0255
    as

    Download full text from publisher

    File URL: http://dx.doi.org/10.1287/inte.1060.0255
    Download Restriction: no
    File URL: https://libkey.io/10.1287/inte.1060.0255?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Grabowski, Henry G. & Vernon, John M., 1994. "Returns to R&D on new drug introductions in the 1980s," Journal of Health Economics, Elsevier, vol. 13(4), pages 383-406.
    2. De Reyck, Bert & Degraeve, Zeger & Vandenborre, Roger, 2008. "Project options valuation with net present value and decision tree analysis," European Journal of Operational Research, Elsevier, vol. 184(1), pages 341-355, January.
    3. Frank M. Bass, 1969. "A New Product Growth for Model Consumer Durables," Management Science, INFORMS, vol. 15(5), pages 215-227, January.
    4. Gary L. Lilien & Ambar G. Rao & Shlomo Kalish, 1981. "Bayesian Estimation and Control of Detailing Effort in a Repeat Purchase Diffusion Environment," Management Science, INFORMS, vol. 27(5), pages 493-506, May.
    5. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Murali Agastya & Oleksii Birulin, 2023. "Optimal Task Scheduling under Adverse Selection and Hidden Actions," American Economic Journal: Microeconomics, American Economic Association, vol. 15(2), pages 660-698, May.
    2. Valdivia, Miguel & Galan, Jose Luis & Laffarga, Joaquina & Ramos, Juan-Luis, 2020. "A research and technology valuation model for decision analysis in the environmental and renewable energy sectors," Renewable and Sustainable Energy Reviews, Elsevier, vol. 122(C).
    3. Mario Barchi & Marco Greco, 2018. "Negotiation in Open Innovation: A Literature Review," Group Decision and Negotiation, Springer, vol. 27(3), pages 343-374, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Orbach Yair & Fruchter Gila E., 2010. "A Utility-Based Diffusion Model Applied to the Digital Camera Case," Review of Marketing Science, De Gruyter, vol. 8(1), pages 1-28, June.
    2. Gleason, Katherine I. & Klock, Mark, 2006. "Intangible capital in the pharmaceutical and chemical industry," The Quarterly Review of Economics and Finance, Elsevier, vol. 46(2), pages 300-314, May.
    3. Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
    4. Islam, Towhidul & Meade, Nigel, 2000. "Modelling diffusion and replacement," European Journal of Operational Research, Elsevier, vol. 125(3), pages 551-570, September.
    5. Chul-Yong Lee & Sung-Yoon Huh, 2017. "Technology Forecasting Using a Diffusion Model Incorporating Replacement Purchases," Sustainability, MDPI, vol. 9(6), pages 1-14, June.
    6. Delre, S.A. & Jager, W. & Bijmolt, T.H.A. & Janssen, M.A., 2007. "Targeting and timing promotional activities: An agent-based model for the takeoff of new products," Journal of Business Research, Elsevier, vol. 60(8), pages 826-835, August.
    7. Chul-Yong Lee & Min-Kyu Lee, 2017. "Demand Forecasting in the Early Stage of the Technology’s Life Cycle Using a Bayesian Update," Sustainability, MDPI, vol. 9(8), pages 1-15, August.
    8. Kim, Namwoon & Srivastava, Rajendra K. & Han, Jin K., 2001. "Consumer decision-making in a multi-generational choice set context," Journal of Business Research, Elsevier, vol. 53(3), pages 123-136, September.
    9. S. Buxton & Kostas Nikolopoulos & M. Khammash & P. Stern, 2015. "Modelling and Forecasting Branded and Generic Pharmaceutical Life Cycles: Assessment of the Number of Dispensed Units," Working Papers 15004, Bangor Business School, Prifysgol Bangor University (Cymru / Wales).
    10. Toole, Andrew A., 2012. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," Research Policy, Elsevier, vol. 41(1), pages 1-12.
    11. Lee, Hakyeon & Kim, Sang Gook & Park, Hyun-woo & Kang, Pilsung, 2014. "Pre-launch new product demand forecasting using the Bass model: A statistical and machine learning-based approach," Technological Forecasting and Social Change, Elsevier, vol. 86(C), pages 49-64.
    12. Dahm, Matthias & González, Paula & Porteiro, Nicolás, 2009. "Trials, tricks and transparency: How disclosure rules affect clinical knowledge," Journal of Health Economics, Elsevier, vol. 28(6), pages 1141-1153, December.
    13. Martin E. Backhouse, 1998. "An investment appraisal approach to clinical trial design," Health Economics, John Wiley & Sons, Ltd., vol. 7(7), pages 605-619, November.
    14. Marc Fischer & Peter Leeflang & Peter Verhoef, 2010. "Drivers of peak sales for pharmaceutical brands," Quantitative Marketing and Economics (QME), Springer, vol. 8(4), pages 429-460, December.
    15. Jongsu Lee & Chul-Yong Lee, 2009. "A Forecasting Model Incorporating Replacement Purchase: Mobile Handsets in South Korea's Market," TEMEP Discussion Papers 200904, Seoul National University; Technology Management, Economics, and Policy Program (TEMEP), revised Apr 2009.
    16. Costello, Christopher & Ward, Michael, 2006. "Search, bioprospecting and biodiversity conservation," Journal of Environmental Economics and Management, Elsevier, vol. 52(3), pages 615-626, November.
    17. Daniel R. Wilmoth, 2015. "Reconciling Estimates of the Value to Firms of Reduced Regulatory Delay in the Marketing of Their New Drugs," Health Economics, John Wiley & Sons, Ltd., vol. 24(12), pages 1651-1656, December.
    18. Anita Elberse & Jehoshua Eliashberg, 2003. "Demand and Supply Dynamics for Sequentially Released Products in International Markets: The Case of Motion Pictures," Marketing Science, INFORMS, vol. 22(3), pages 329-354.
    19. Christophe Van den Bulte & Yogesh V. Joshi, 2007. "New Product Diffusion with Influentials and Imitators," Marketing Science, INFORMS, vol. 26(3), pages 400-421, 05-06.
    20. Yaroslav Kryukov, "undated". "Dynamic R&D and the Effectiveness of Policy Intervention in the Pharmaceutical Industry," GSIA Working Papers 2015-E33, Carnegie Mellon University, Tepper School of Business.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:inm:orinte:v:37:y:2007:i:5:p:472-487. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Chris Asher (email available below). General contact details of provider: https://edirc.repec.org/data/inforea.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.